Akero's CEO comments on today's 96 week MASH data and the future of efruxifermin
- Jan 27, 2025
- 1 min read
Andrew Cheng describes the F4 patient population, and dicusses the efficacy and safety data Akero saw today. Plus, ongoing trials and how the company thinks about business development.









.png)
